Olumiant (baricitinib) vs Veklury (remdesivir)
Olumiant (baricitinib) vs Veklury (remdesivir)
Olumiant (baricitinib) is an oral Janus kinase (JAK) inhibitor that is primarily used to treat moderate to severe rheumatoid arthritis and has also been investigated for its anti-inflammatory properties in the context of COVID-19. Veklury (remdesivir), on the other hand, is an antiviral medication administered intravenously and is specifically indicated for the treatment of COVID-19 in hospitalized patients. When deciding between the two medications for COVID-19, it is essential to consult with a healthcare provider to consider factors such as the severity of the disease, underlying health conditions, and the mechanism of action of each drug, as Olumiant is generally considered when an immune response modulating therapy is needed, whereas Veklury is chosen for its direct antiviral effects.
Difference between Olumiant and Veklury
| Metric | Olumiant (baricitinib) | Veklury (remdesivir) |
|---|---|---|
| Generic name | Baricitinib | Remdesivir |
| Indications | Rheumatoid arthritis, COVID-19 (under Emergency Use Authorization) | COVID-19 |
| Mechanism of action | Janus kinase (JAK) inhibitor, which interferes with the JAK-STAT signaling pathway | Adenosine nucleotide analog, which interferes with the action of viral RNA polymerase |
| Brand names | Olumiant | Veklury |
| Administrative route | Oral | Intravenous |
| Side effects | Upper respiratory tract infections, nausea, headache, hypertension | Nausea, ALT elevations, hypersensitivity reactions |
| Contraindications | Active serious infections, hypersensitivity to baricitinib | Hypersensitivity to remdesivir or any component of the formulation |
| Drug class | Janus kinase inhibitor | Antiviral |
| Manufacturer | Eli Lilly and Company | Gilead Sciences |
Efficacy
Efficacy of Olumiant (Baricitinib) in Treating COVID-19
Olumiant (baricitinib) is an oral medication initially approved for the treatment of moderate to severe rheumatoid arthritis. However, its role in the treatment of COVID-19 has been investigated due to its anti-inflammatory properties. Baricitinib is a Janus kinase (JAK) inhibitor that can interfere with the pathway that leads to inflammation. In the context of COVID-19, the drug has been studied for its potential to reduce the cytokine storm associated with severe disease, which can lead to acute respiratory distress syndrome (ARDS) and other complications.
Clinical trials have shown that baricitinib, in combination with the antiviral drug remdesivir, can provide a benefit in treating hospitalized adults with COVID-19. According to data from the Adaptive COVID-19 Treatment Trial (ACTT-2), patients who received baricitinib plus remdesivir had a shorter time to recovery than those who received remdesivir alone. This combination also appeared to improve the clinical status of patients, particularly those receiving high-flow oxygen or non-invasive ventilation. The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for baricitinib in combination with remdesivir for the treatment of certain hospitalized patients with COVID-19.
Efficacy of Veklury (Remdesivir) in Treating COVID-19
Veklury (remdesivir) is an antiviral medication that has been one of the primary treatments for COVID-19 since early in the pandemic. It works by inhibiting the replication of the SARS-CoV-2 virus, which causes COVID-19. Remdesivir has been shown to be most effective in treating patients with COVID-19 when administered early in the course of the disease, particularly in those who require supplemental oxygen but are not yet on mechanical ventilation or extracorporeal membrane oxygenation (ECMO).
The efficacy of remdesivir was initially demonstrated in the ACTT-1 trial, where it was shown to reduce the time to recovery in hospitalized patients with COVID-19. Following this, the FDA approved remdesivir for the treatment of COVID-19 in hospitalized patients. Remdesivir has been widely used around the world and is often considered a standard part of the treatment regimen for patients with severe COVID-19, although its use and recommendations may evolve with emerging clinical data and the development of other therapeutic agents.
Regulatory Agency Approvals
Olumiant
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
-
Therapeutic Goods Administration (TGA), Australia
Veklury
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
-
Health Canada
-
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
-
Therapeutic Goods Administration (TGA), Australia
Access Olumiant or Veklury today
If Olumiant or Veklury are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us